Immunotherapy

© GettyImages/Lars Neumann

KIYATEC flags checkpoint inhibitor response prediction milestone

By Jane Byrne

US company, KIYATEC, says a new study has shown that its immune-modified ex vivo platform can measure treatment response through direct interaction between a patient's cancer and infiltrating immune cells, and immuno-oncology agents.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers